DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
| You are receiving this because you have an account on www.oneGRAVESvoice.com | ||
| To unsubscribe from these emails, click here |
Trusted Resources: Community Center
Online groups, photo galleries and blogs
Jake: Graves’ Disease and Agent Orange
The Graves’ Disease & Thyroid Foundation recently received an update from community member Jake George and is sharing his story with permission:
I received notification from the VA yesterday that my thyroid eye disease was approved secondary to my thyroid disease as a service related disability due to agent Orange exposure. I received a rating of 30% disability. What this means is the VA determined my thyroid disease was caused by my exposure to agent orange and my TED was caused by my thyroid disease so both are covered by the VA. If you are a veteran who was exposed to agent orange visit the VA www.va.gov to review the PACT act to see if you qualify.
myBinderRelated Content
-
Evidence & EducationEfficacy and Safety of Immunosuppressive Agents for Thyroid Eye DiseasePurpose: To present an update on the ef...
-
Videos & VisualsStanford Doctor Discusses Thyroid Eye Disease: Understanding the Disease and New Treatmentshttps://www.youtube.com/watch?v=clBkmWQi...
-
Videos & VisualsGraves’ Disease Symposium Questions and Answers (Pediatric)https://www.youtube.com/watch?v=EtKbS0zE...
-
Evidence & EducationGlucocorticoid Regimens for Prevention of Graves’ Ophthalmopathy Progression Following Radioiodine Treatment: ...Background: Glucocorticoid (GC) therapy...
-
People & PlacesElizabeth A. Bradley, MDElizabeth A. Bradley is an ophthalmologi...
-
People & PlacesDavid B. Granet, MD, FAAO, FACS, FAAPDavid B. Granet is the Anne Ratner Chair...
-
Evidence & EducationPediatric Graves’ Disease: Controversies in ManagementBackground/Aims: Graves' disease (GD) i...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.